Lv51
930 积分 2023-06-15 加入
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide
1小时前
待确认
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
1小时前
待确认
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
1小时前
待确认
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
2小时前
待确认
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial
3小时前
待确认
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
3小时前
待确认
The incidence of surgical site infections in China
23天前
已完结
Local prolonged release of antibiotic for prevention of sternal wound infections postcardiac surgery—A novel technology
27天前
已完结
Trifluridine–tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study
28天前
已完结
406P Real-world evidence of efficacy and safety in first-line cetuximab treatment of RAS wild-type metastatic colorectal cancer: A multicenter retrospective study in Taiwan
28天前
已完结
皖公网安备34019202002308
